Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) EBT Margin (2017 - 2025)

Historic EBT Margin for UroGen Pharma (URGN) over the last 9 years, with Q3 2025 value amounting to 125.18%.

  • UroGen Pharma's EBT Margin fell 316100.0% to 125.18% in Q3 2025 from the same period last year, while for Sep 2025 it was 167.47%, marking a year-over-year decrease of 428800.0%. This contributed to the annual value of 137.22% for FY2024, which is 183400.0% down from last year.
  • Latest data reveals that UroGen Pharma reported EBT Margin of 125.18% as of Q3 2025, which was down 316100.0% from 202.04% recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's EBT Margin peaked at 93.56% during Q3 2024, and registered a low of 346.49% during Q1 2021.
  • Its 5-year average for EBT Margin is 171.05%, with a median of 160.56% in 2022.
  • In the last 5 years, UroGen Pharma's EBT Margin skyrocketed by 82283300bps in 2021 and then plummeted by -493300bps in 2025.
  • Quarter analysis of 5 years shows UroGen Pharma's EBT Margin stood at 168.88% in 2021, then increased by 8bps to 155.76% in 2022, then skyrocketed by 40bps to 94.19% in 2023, then tumbled by -51bps to 141.92% in 2024, then increased by 12bps to 125.18% in 2025.
  • Its last three reported values are 125.18% in Q3 2025, 202.04% for Q2 2025, and 214.53% during Q1 2025.